189 related articles for article (PubMed ID: 20233883)
61. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study.
Hallermann C; Niermann C; Fischer RJ; Schulze HJ
Acta Derm Venereol; 2011 Sep; 91(5):521-5. PubMed ID: 21547335
[TBL] [Abstract][Full Text] [Related]
62. cDNA microarrays: revolutionary technology for the diagnosis, prognosis, and treatment of cutaneous T-cell lymphoma.
Hinshaw MA; Wood GS
Int J Dermatol; 2005 Mar; 44(3):181-3. PubMed ID: 15807722
[No Abstract] [Full Text] [Related]
63. [Interferon-alpha in cutaneous T-cell lymphoma].
Knobler R
Wien Med Wochenschr; 1993; 143(16-17):435-7. PubMed ID: 8273368
[TBL] [Abstract][Full Text] [Related]
64. Immunohistochemical staining for CD45R isoforms in paraffin sections to diagnose mycosis fungoides-type cutaneous T-cell lymphoma.
Ismail SA; Han R; Sanborn SL; Stevens SR; Cooper KD; Wood GS; Gilliam AC
J Am Acad Dermatol; 2007 Apr; 56(4):635-42. PubMed ID: 17367612
[TBL] [Abstract][Full Text] [Related]
65. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Witkiewicz A; Raghunath P; Wasik A; Junkins-Hopkins JM; Jones D; Zhang Q; Odum N; Wasik MA
Hum Pathol; 2007 Mar; 38(3):462-7. PubMed ID: 17239936
[TBL] [Abstract][Full Text] [Related]
66. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
67. Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Kawaguchi M; Takahashi N; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2014 Aug; 20(16):4339-48. PubMed ID: 24919568
[TBL] [Abstract][Full Text] [Related]
68. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).
Ralfkiaer U; Hagedorn PH; Bangsgaard N; Løvendorf MB; Ahler CB; Svensson L; Kopp KL; Vennegaard MT; Lauenborg B; Zibert JR; Krejsgaard T; Bonefeld CM; Søkilde R; Gjerdrum LM; Labuda T; Mathiesen AM; Grønbæk K; Wasik MA; Sokolowska-Wojdylo M; Queille-Roussel C; Gniadecki R; Ralfkiaer E; Geisler C; Litman T; Woetmann A; Glue C; Røpke MA; Skov L; Odum N
Blood; 2011 Nov; 118(22):5891-900. PubMed ID: 21865341
[TBL] [Abstract][Full Text] [Related]
69. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.
Krejsgaard T; Vetter-Kauczok CS; Woetmann A; Kneitz H; Eriksen KW; Lovato P; Zhang Q; Wasik MA; Geisler C; Ralfkiaer E; Becker JC; Ødum N
Blood; 2009 Jun; 113(23):5896-904. PubMed ID: 19351960
[TBL] [Abstract][Full Text] [Related]
70. Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.
Lefebvre MN; Borcherding N; Reis RJ; Mou E; Liu V; Jabbari A
Front Immunol; 2023; 14():1228563. PubMed ID: 37654486
[TBL] [Abstract][Full Text] [Related]
71. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583
[TBL] [Abstract][Full Text] [Related]
72. Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage.
Vasku A; Vasku JB; Necas M; Vasku V
J Biomed Biotechnol; 2010; 2010():805907. PubMed ID: 20625418
[TBL] [Abstract][Full Text] [Related]
73. Cutaneous T-cell lymphoma with intracerebral and bilateral intraocular spread.
Wylen EL; Williams RB; Nanda A
Neurol Res; 1998 Jun; 20(4):307-12. PubMed ID: 9618693
[TBL] [Abstract][Full Text] [Related]
74. Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.
Humme D; Haider A; Möbs M; Mitsui H; Suárez-Fariñas M; Ohmatsu H; Isabell Geilen C; Eberle J; Krueger JG; Beyer M; Hummel M; Anagnostopoulos I; Sterry W; Assaf C
J Invest Dermatol; 2015 Sep; 135(9):2292-2300. PubMed ID: 25848977
[TBL] [Abstract][Full Text] [Related]
75. Immunodiagnosis in cutaneous T cell lymphoma: how does gene expression of the variable region of the T cell receptor fit into the diagnostic and pathophysiological picture of T cell neoplasia.
Fivenson DP; Nickoloff BJ
J Cutan Pathol; 1992 Feb; 19(1):1-5. PubMed ID: 1556262
[No Abstract] [Full Text] [Related]
76. The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma.
Rook AH; McGinnis KS; Richardson SK; Budgin JB; Wysocka M; Benoit BM; Hopkins JM; Vittorio CC
Dermatol Ther; 2003; 16(4):331-6. PubMed ID: 14686976
[TBL] [Abstract][Full Text] [Related]
77. Cutaneous T-cell lymphoma (CTCL) patients' understanding of illness and perception of follow-up.
Torosian A; Albucker SJ; Gowda G; Boh E; Bitar C
Int J Dermatol; 2023 Dec; 62(12):e645-e647. PubMed ID: 37548249
[No Abstract] [Full Text] [Related]
78. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas.
Marstrand T; Ahler CB; Ralfkiaer U; Clemmensen A; Kopp KL; Sibbesen NA; Krejsgaard T; Litman T; Wasik MA; Bonefeld CM; Grønbæk K; Gjerdum LM; Gniadecki R; Ralfkiaer E; Geisler C; Woetmann A; Røpke MA; Glue C; Skov L; Odum N
Leuk Lymphoma; 2014 Apr; 55(4):957-8. PubMed ID: 23772646
[No Abstract] [Full Text] [Related]
79. FISH Panel for Leukemic CTCL.
Weed J; Gibson J; Lewis J; Carlson K; Foss F; Choi J; Li P; Girardi M
J Invest Dermatol; 2017 Mar; 137(3):751-753. PubMed ID: 27836797
[No Abstract] [Full Text] [Related]
80. Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma.
Heald P
Ann N Y Acad Sci; 2001 Sep; 941():155-65. PubMed ID: 11594569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
